Compare CVS Health Corp (CVS) vs JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs JPMorgan Nasdaq Equity Premium Income ETF — how do they compare? CVS Health Corp trades at $85.77 (market cap $112.29B), while JPMorgan Nasdaq Equity Premium Income ETF trades at $61.19 (market cap $44.49B). The key difference: CVS Health Corp is far larger — about 2.5× JPMorgan Nasdaq Equity Premium Income ETF's market cap, and CVS Health Corp pays a 3.03% dividend while JPMorgan Nasdaq Equity Premium Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and JPMorgan Nasdaq Equity Premium Income ETF for 65 Days on average.
| CVS | JEPQ | |
|---|---|---|
Market Cap | $112.29B | $44.49B |
Volume | 7,763,676 | 5,681,789 |
Sector | Health | Income / Options Overlay |
52-Week High | $110.60 | $61.46 |
52-Week Low | $70.08 | $53.77 |
Typical Hold Time | 83 Days | 65 Days |
Enterprise Value | $174.64B | — |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
JEPQ trades at $61.27, showing minimal daily movement with a 0.03% gain. The ETF maintains a bullish technical outlook with strong moving average support, though oscillators signal some near-term caution. Recent dividend distributions of $0.57-$0.70 demonstrate the fund's income generation capability, with financial media highlighting its 11% estimated yield and positioning for AI infrastructure growth.
The covered-call strategy provides downside protection but limits upside potential during strong bull markets. Institutional interest remains positive with recent acquisitions, though investors should note the variable nature of distributions and the trade-off between high current income and long-term capital appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →
